Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX)
CUSIP: 03237H101
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 109,540,561
- Total 13F shares
- 81,690,006
- Share change
- +7,785,015
- Total reported value
- $523,632,250
- Put/Call ratio
- 7.2%
- Price per share
- $6.41
- Number of holders
- 131
- Value change
- +$57,316,535
- Number of buys
- 67
- Number of sells
- 74
Quarterly Holders Quick Answers
What is CUSIP 03237H101?
CUSIP 03237H101 identifies AMLX - Amylyx Pharmaceuticals, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 03237H101:
Top shareholders of AMLX - Amylyx Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ALS Invest 1 B.V. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
5,895,280
|
$96,258,721 | — | 06 Jul 2022 | |
| Morningside Venture Investments Ltd |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,997,302
|
$81,596,447 | — | 15 Aug 2023 | |
| DRAGSA 96 LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,300,000
|
$37,554,630 | — | 11 Jan 2022 | |
| VIKING GLOBAL INVESTORS LP |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,850,940
|
$30,222,333 | — | 08 Sep 2022 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
7.2%
|
7,874,348
|
$27,875,192 | — | 31 Mar 2025 | |
| TCG Crossover Management, LLC |
13F
|
Company |
5.4%
|
5,943,812
|
$21,041,094 | — | 31 Mar 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
5.2%
|
5,697,605
|
$20,169,522 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.8%
|
4,116,512
|
$14,572,453 | — | 31 Mar 2025 | |
| Panacea Innovation Ltd |
13D/G
|
Panacea Venture Healthcare Fund II, L.P. |
2.6%
|
2,200,000
|
$11,792,000 | $0 | 31 Dec 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
2.8%
|
3,081,853
|
$10,909,760 | — | 31 Mar 2025 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
2.7%
|
2,934,405
|
$10,387,794 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
2.5%
|
2,757,776
|
$9,762,527 | — | 31 Mar 2025 | |
| Aberdeen Group plc |
13F
|
Company |
2.2%
|
2,430,358
|
$8,603,467 | — | 31 Mar 2025 | |
| Saturn V Capital Management LP |
13F
|
Company |
2.2%
|
2,426,436
|
$8,589,583 | — | 31 Mar 2025 | |
| 683 Capital Management, LLC |
13F
|
Company |
2.2%
|
2,411,400
|
$8,536,356 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
2.2%
|
2,387,409
|
$8,451,427 | — | 31 Mar 2025 | |
| Almitas Capital LLC |
13F
|
Company |
1.9%
|
2,122,597
|
$7,513,993 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.8%
|
2,002,961
|
$7,090,483 | — | 31 Mar 2025 | |
| GREAT POINT PARTNERS LLC |
13F
|
Company |
1.7%
|
1,811,996
|
$6,414,466 | — | 31 Mar 2025 | |
| Boxer Capital Management, LLC |
13F
|
Company |
1.6%
|
1,750,000
|
$6,195,000 | — | 31 Mar 2025 | |
| Woodline Partners LP |
13F
|
Company |
1.5%
|
1,609,447
|
$5,697,442 | — | 31 Mar 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
1.3%
|
1,471,587
|
$5,209,418 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
1.3%
|
1,470,925
|
$5,207,075 | — | 31 Mar 2025 | |
| Margaret Olinger |
3/4/5
|
Chief Commercial Officer |
—
mixed-class rows
|
320,685
mixed-class rows
|
$5,178,792 | — | 27 Dec 2023 | |
| UBS Group AG |
13F
|
Company |
1.3%
|
1,388,427
|
$4,915,032 | — | 31 Mar 2025 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
1.1%
|
1,199,691
|
$4,246,906 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
1.1%
|
1,157,988
|
$4,099,278 | — | 31 Mar 2025 | |
| Patrick D. Yeramian |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
239,375
mixed-class rows
|
$3,357,139 | — | 09 Jan 2024 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.86%
|
942,891
|
$3,337,834 | — | 31 Mar 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.84%
|
916,966
|
$3,246,060 | — | 31 Mar 2025 | |
| PFM Health Sciences, LP |
13F
|
Company |
0.76%
|
834,135
|
$2,952,838 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.74%
|
806,161
|
$2,854,903 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.73%
|
794,354
|
$2,812,013 | — | 31 Mar 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.7%
|
762,053
|
$2,697,668 | — | 31 Mar 2025 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
0.69%
|
750,412
|
$2,656,458 | — | 31 Mar 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.59%
|
649,800
|
$2,300,292 | — | 31 Mar 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.52%
|
570,857
|
$2,020,834 | — | 31 Mar 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.47%
|
515,100
|
$1,823,454 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.43%
|
474,418
|
$1,679,440 | — | 31 Mar 2025 | |
| CITIGROUP INC |
13F
|
Company |
0.42%
|
463,240
|
$1,639,870 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.34%
|
372,853
|
$1,319,900 | — | 31 Mar 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.32%
|
348,000
|
$1,231,920 | — | 31 Mar 2025 | |
| Rock Springs Capital Management LP |
13F
|
Company |
0.31%
|
343,228
|
$1,215,027 | — | 31 Mar 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.3%
|
331,185
|
$1,172,395 | — | 31 Mar 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.27%
|
290,682
|
$1,029,015 | — | 31 Mar 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.25%
|
270,006
|
$955,821 | — | 31 Mar 2025 | |
| Allostery Investments LP |
13F
|
Company |
0.24%
|
266,099
|
$941,990 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.24%
|
261,783
|
$926,712 | — | 31 Mar 2025 | |
| Aldebaran Capital, LLC |
13F
|
Company |
0.24%
|
259,253
|
$917,756 | — | 31 Mar 2025 | |
| Walleye Capital LLC |
13F
|
Company |
0.23%
|
250,888
|
$888,144 | — | 31 Mar 2025 |
Institutional Holders of Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX) as of Q2 2025
As of 30 Jun 2025,
Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX) was held by
131 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
81,690,006 shares.
The largest 10 holders included
ADAGE CAPITAL PARTNERS GP, L.L.C., PERCEPTIVE ADVISORS LLC, TCG Crossover Management, LLC, BlackRock, Inc., Point72 Asset Management, L.P., VANGUARD GROUP INC, Saturn V Capital Management LP, FMR LLC, Nantahala Capital Management, LLC, and 683 Capital Management, LLC.
This page lists
131
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
134
Q2 2025 holders
131
Holder diff
-3
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.